Skip to main content

Table 4 Univariate analysis of factors affecting RFS of patients with adjuvant therapy

From: KIBRA; a novel biomarker predicting recurrence free survival of breast cancer patients receiving adjuvant therapy

Clinico-pathological feature Chemotherapy Endocrine therapy
p value (HR;CI) p value (HR;CI)
Age (≤35, 36–60, > 60 years) 0.598 (0.919; 0.670–1.260) 0.979 (1.011; 0.463–2.205)
Nottingham grade 0.052 (1.290; 0.998–1.668) 0.010 (2.355; 1.225–4.526)
Tumour size (< 2, 2–5, > 5 cm) 0.109 (1.249; 0.952–1.640) 0.320 (1.413; 0.713–2.806)
Presence or absence of lymph node metastasis 0.002 (0.575; 0.408–0.809) 0.467 (0.739; 0.327–1.669)
Lymph node stage < 0.001 (1.370; 1.183–1.587) 0.096 (1.370; 0.946–1.984)
TNM stage < 0.001 (1.792; 1.399–2.296) 0.036 (1.884; 1.041–3.408)
Lympho-vascular invasion 0.061 (0.856; 0.727–1.007) 0.014 (0.604; 0.404–0.902)
ER expression 0.031 (1.468; 1.036–2.079)
PgR expression 0.007 (1.608; 1.137–2.274)
HER2 over-expression 0.016 (0.789; 0.651–0.956) 0.003 (0.484; 0.302–0.777)
KIBRA – 4 groups 0.231 (1.098; 0.942–1.279) 0.166 (1.279; 0.903–1.813)
KIBRA-low 0.019 (0.649; 0.451–0.932) 0.025 (0.389; 0.170–0.890)
Molecular subtype 0.078 (1.092; 0.990–1.203) 0.063 (1.489; 0.979–2.264)
Ki 67 ≥ 14% cells 0.546 (0.875; 0.566–1.351) 0.245 (0.558; 0.209–1.492)
  1. p, significance; ER, estrogen expression; PgR, progesterone expression; HER2, human epidermal growth factor receptor2; KIBRA-low, low expression of KIBRA in both cytoplasm and nucleus